December 16, 2025
Cellectis Announces Arbitral Decision in Dispute with Servier
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology…
Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology…
MISSISSAUGA, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce…
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE…
AUSTIN, TX and DURHAM, NC, Dec. 15, 2025 (GLOBE NEWSWIRE) — Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK),…
Abivax Presents Third Quarter 2025 Financial Results Cash and cash equivalents of EUR 589.7 (as of September 30, 2025) with…
– AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new…
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate…
Findings provide scientific insights into the contributions of IDO1 and PD-L1 vaccination to PD-1 blockade for the treatment of metastatic…
Conference call and webcast to be held at 8 a.m. ET on December 16, 2025BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE)…
EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) — Kyverna Therapeutics, Inc. (Nasdaq: KYTX) (“Kyverna”), a clinical-stage biopharmaceutical company focused on…